A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : GEJ / gastroesophageal junction

[Related PubMed/MEDLINE]
Total Number of Papers: 650
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   GEJ  (>> Co-occurring Abbreviation)
Long Form:   gastroesophageal junction
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2023 Contemporary outcomes of esophageal and gastroesophageal junction neuroendocrine tumors. ---
2023 Efficacy and safety of camrelizumab plus chemotherapy versus chemotherapy alone in patients with untreated, HER2-negative, unresectable locally advanced, or metastatic gastric cancer or gastroesophageal junction cancer: a retrospective comparative cohort study. CapeOX, CI, CPS, DCR, EBV, GC, HER2, HR, NLR, ORR, OS, PD-L1, PFS, TRAEs
2023 Efficacy and safety of neoadjuvant immunotherapy in resectable esophageal or gastroesophageal junction carcinoma: A pooled analysis of prospective clinical trials. AEs, ESCC, ICIs, nCRT
2023 Event-free survival as a surrogate for overall survival in gastric and gastroesophageal junction adenocarcinoma: A meta-analysis in the neoadjuvant ±adjuvant setting. CI, EFS, HR, OS, RCTs
2023 Evidence-Based Surgical Approach to Gastroesophageal Junction Cancer: How We Do Robotic Transhiatal Lower Mediastinal Dissection and Esophagojejunostomy. LN
2023 Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline. AC, CPS, CT, HER2, PD-L1
2023 Survival after Ivor Lewis versus McKeown esophagectomy for cancer: propensity score matched analysis. IL, McK, RS
2022 A phase 1b study of andecaliximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma. ADX, AEs, MMP-9, SOX, SP
2022 A population-based study on treatment and outcomes in patients with gastric adenocarcinoma diagnosed with distant interval metastases. OS
10  2022 A study protocol of a randomized phase II trial of perioperative chemoimmunotherapy verses perioperative chemoimmunotherapy plus preoperative chemoradiation for locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma: the NeoRacing study. AGC, CHT, CRT, EFS, LAGC, ORR, OS, pCR, pPR
11  2022 Adenocarcinoma of the Gastroesophageal Junction Masquerading as Mallory-Weiss Syndrome. EGD, MWS
12  2022 Adjuvant Chemoradiotherapy Versus Adjuvant Chemotherapy for Stage III Gastric or Gastroesophageal Junction Cancer After D2/R0 Resection. CRT, CT, OS, PSM
13  2022 Assessment and validation of the internal gross tumour volume of gastroesophageal junction cancer during simultaneous integrated boost radiotherapy. 4DCT, AP, CBCT, CC, IGTV, LR
14  2022 ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications. ---
15  2022 Body composition dynamics and impact on clinical outcome in gastric and gastro-esophageal junction cancer patients undergoing perioperative chemotherapy with the FLOT protocol. BMI
16  2022 Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort. OS, PFS, PS
17  2022 Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan. CPS, EBV, MSI-H, PD-L1
18  2022 Comparison of neoadjuvant regimens for resectable gastroesophageal junction cancer: a systematic review of randomized clinical trials across three decades. CI, CRT, CT, ITT, OS, RCTs, RT
19  2022 Differences in clinicopathology and prognosis between gastroesophageal junctional and gastric non-cardiac neuroendocrine carcinomas: a retrospective comparison study of consecutive 56 cases from a single institution in China. MiNEN, NEC
20  2022 Does radiomics play a role in the diagnosis, staging and re-staging of gastroesophageal junction adenocarcinoma? RQS
21  2022 Does the Computed Tomography Hounsfield Units Change Predict Response to Perioperative Chemotherapy in Patients with Gastric Adenocarcinoma. CT, FU, GC, LV
22  2022 Dramatic Response to Trastuzumab Deruxtecan Rechallenge in a Patient with HER2-Positive Gastric Cancer: A Case Report. HER2
23  2022 Dual-layer dual-energy CT for improving differential diagnosis of squamous cell carcinoma from adenocarcinoma at gastroesophageal junction. AC, AP, IC, ROC, SCC, SDCT, VP
24  2022 Dynamic changes in systemic immune-inflammation index predict pathological tumor response and overall survival in patients with gastric or gastroesophageal junction cancer receiving neoadjuvant chemotherapy. DeltaSII, DFS and OS, HR, NACT, SII, TRG
25  2022 Efficacy and Safety of Sintilimab in Combination with Concurrent Chemoradiotherapy for Locally Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (SHARED): Study Protocol of a Prospective, Multi-Center, Single-Arm Phase 2 Trial. CCRT, DFS, EFS, MPR, OS, pCR, PD-1
26  2022 Esophagectomy vs Gastrectomy for Early Stage Adenocarcinoma of the Gastroesophageal Junction: What is the Optimal Oncologic Surgical Treatment? KM, OS, PSM
27  2022 Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. D1D8, EDRs, PFS
28  2022 Evaluation of Tumor DNA Sequencing Results in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma Stratified by TP53 Mutation Status. GC, TP53 MUT
29  2022 Factors associated with pathologic complete response following neoadjuvant chemoradiation and esophagectomy for carcinoma of esophagus and gastroesophageal junction. NCRT, pCR, SCC
30  2022 First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer. CF, OS, PFS
31  2022 Gastrectomy for Cancer: A 15-Year Analysis of Real-World Data from the University of Athens. DFS, OS
32  2022 Generation and multiomic profiling of a TP53/CDKN2A double-knockout gastroesophageal junction organoid model. CDKN2A, FOXM1, PTAFR, PTAFs, TP53
33  2022 Heterotopic Pancreas Located at the Gastroesophageal Junction in a Hiatal Hernia: A Case Report. ---
34  2022 Identification and Somatic Characterization of the Germline PTEN Promoter Variant rs34149102 in a Family with Gastrointestinal and Breast Tumors. PHTS
35  2022 Impedance planimetry (EndoFLIP™) after magnetic sphincter augmentation (LINX®) compared to fundoplication. DI, FLIP, LF, MSA, RSI
36  2022 Impedance planimetry (EndoFLIP™) reveals changes in gastroesophageal junction compliance during fundoplication. DI
37  2022 Intraoperative near-infrared lymphography with indocyanine green may aid lymph node dissection during robot-assisted resection of gastroesophageal junction cancer. ICG, IQR, LN, NIR
38  2022 Is there a role for upper gastrointestinal contrast study to predict the outcomes of sleeve gastrectomy? Lessons learnt from a prospective study. GDE, GERD, SG, UGI
39  2022 Management of Clinical T2N0 Esophageal and Gastroesophageal Junction Adenocarcinoma: What Is the Optimal Treatment? AT, cT2N0, NAT
40  2022 Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial. CI
41  2022 Neoadjuvant Chemoradiotherapy versus Chemotherapy for Gastroesophageal Junction Adenocarcinoma; Which Is the Optimal Treatment Option? CT, NAT, RCT
42  2022 Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. dMMR, MSI-H, pCR
43  2022 Neoadjuvant Treatment Strategies for Resectable Proximal Gastric, Gastroesophageal Junction and Distal Esophageal Cancer. AC, SCC
44  2022 Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction. CPS, EV, OS, PD, PFS, TME
45  2022 Perioperative treatment and biomarker analysis of LP002, an anti-PD-L1 antibody, plus chemotherapy in resectable gastric and gastroesophageal junction cancer. mIF, NGS, pCR, TRAEs, TRG
46  2022 Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR). FLOT, OS, pCR
47  2022 Population-Based Cohort Study from a Prospective National Registry: Better Long-Term Survival in Esophageal Cancer After Minimally Invasive Compared with Open Transthoracic Esophagectomy. ASA, CI, HMIE, HR, MIE, OE, OR, TMIE
48  2022 Preferred neoadjuvant therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis. CT, HRs, NMA, OS and DFS, SUCRA
49  2022 Prevalence of microsatellite instable and Epstein-Barr Virus-driven gastroesophageal cancer in a large Belgian cohort. GEC, IHC, ISH, MSI, MSI-H, PCR
50  2022 Progression-Free Survival as Early Efficacy Endpoint in Resectable Esophageal Cancer Treated With Neoadjuvant Therapy: A Systematic Review. CI, HR, nCRT, OS, PFS, RCTs
51  2022 Quantifying physiologic parameters of the gastroesophageal junction during robotic sleeve gastrectomy and identifying predictors of post-sleeve gastroesophageal reflux disease. CSA, DI, GERD, LES
52  2022 Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16). CI, HER2, OS
53  2022 Randomized, double-blind, placebo-controlled phase 3 study of paclitaxel {plus minus} napabucasin in pretreated advanced gastric or gastroesophageal junction adenocarcinoma. DCR, ORR, OS, PFS
54  2022 Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. DCR, ORR, OS, PFS
55  2022 Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. DFS, GC, NACT, OS, pCR
56  2022 Reconstruction of the Gastro-esophageal Junction Based on Ultramill Imaging for Biomechanical Analysis. ---
57  2022 Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma. GC, mDCF, mOS, mPFS
58  2022 Safety and efficacy of the FLOT regimen in the Polish population - an analysis of the prospective trial. DFS, GC, OS
59  2022 Safety and Efficacy of Treatment with/without Ramucirumab in Advanced or Metastatic Cancer: A Meta-Analysis of 11 Global, Double-Blind, Phase 3 Randomized Controlled Trials. NSCLC, TEAEs
60  2022 Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study. DLTs, HER2, MMP-9, PD-1, PK
61  2022 Safety of FOLFIRI + Durvalumab +/- Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59. AEs, ICI
62  2022 Severe Gastric Mucosal Necrosis Due to Giant Paraesophageal Hernia. PEH
63  2022 Surgical pathology of adenocarcinomas arising around or within the gastroesophageal junction. AC, IHC
64  2022 The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer. AEs, CR, DCR, GC, HER2, irAEs, ORR, PD, PFS, PR, SD
65  2022 The impact of hiatal hernia on survival outcomes in patients with gastroesophageal junction adenocarcinoma. HH, OS, RFS
66  2022 The role of proximal gastrectomy in gastric cancer. GC, PG
67  2022 Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial. HER2
68  2022 Treatment heterogeneity and overall survival in patients with advanced/metastatic gastric or gastroesophageal junction adenocarcinoma in the United States. HHI, NCCN, OS, US
69  2022 Trimodality treatment in gastric and gastroesophageal junction cancers: Current approach and future perspectives. ---
70  2022 Tubularized and Effaced Gastric Cardia Mimicking Barrett Esophagus Following Sleeve Gastrectomy: Protocolized Endoscopic and Histological Assessment With High-resolution Manometry Analysis. BE, HRM
71  2022 Type II hiatal hernias: do they exist or are they actually parahiatal hernias? HH, PEH
72  2022 Validation of the Memorial Sloan Kettering Gastric Cancer Post-Resection Survival Nomogram: Does It Stand the Test of Time? AJCC, DSS, MSK
73  2022 Video-assisted thoracoscopic surgery (VATS) enucleation of large gastroesophageal junction leiomyoma: A case report. CT, EUS, VATS
76  2021 A Patient-Derived Orthotopic Xenograft Model of Gastroesophageal-Junction Adenocarcinoma Translated to the Clinic by Tumor-Targeting Fluorescent Antibodies to Carcinoembryonic-Antigen-Related Cell-Adhesion Molecules. PDOX
77  2021 A Phase II Trial of Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma: A Big Ten Cancer Research Consortium Study. AC, CRT, pCR, RFS
78  2021 A Rare Case of Synchronous Esophageal and Pancreatic Malignancy. ERCP, EUS
79  2021 Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature. ---
80  2021 Autophagic Heterogeneity in Gastric Adenocarcinoma. ---
81  2021 Back to the future: laparoscopic transgastric resection of a subepithelial tumor in the gastroesophageal junction ---
82  2021 Beyond the Guidelines: The Grey Zones of the Management of Gastric Cancer. Consensus Statements from the Gastric Cancer Italian Network (GAIN). GAIN
83  2021 Blastic Mantle Cell Lymphoma of the Gastroesophageal Junction: A Unique Presentation and Literature Review. EGDs, IHC, MCL
84  2021 Comparative effectiveness and tolerability of targeted agents combined with chemotherapy in patients with HER2-positive gastroesophageal cancer: A network meta-analysis. GC, IHC, ISH, LapChemo, OS, PerTraChemo, RCTs, TraChemo, TraD
85  2021 Comparison of Efficacy and Safety of Third-Line Treatments for Advanced Gastric Cancer: A Systematic Review With Bayesian Network Meta-Analysis. AEs, AGC, CrI, DCR, HR, ICIs, mOS, mPFS, NMA, POS, PPFS, RCTs
86  2021 Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830]. ---
87  2021 Cost-effectiveness of trifluridine/tipiracil as a third-line treatment of metastatic gastric cancer, including adenocarcinoma of the gastrohesophageal junction, among patients previously treated in Greece. BSC, ICER, LYs, MGC, QALYs
88  2021 CROSS or FLOT in Distal Esophageal and Gastroesophageal Cancer. ADC, CROSS, FLOT, SCC
89  2021 Distinct Differences in Gastroesophageal Junction and Gastric Adenocarcinoma in 2194 Patients: In Memory of Rebecca A. Carr, February 24, 1988-January 19, 2021. DSS, GC
90  2021 Does Pathological Stage and Nodal Involvement Influence Long Term Oncological Outcomes after CROSS Regimen for Adenocarcinoma of the Esophagogastric Junction? A Multicenter Retrospective Analysis. CROSS, DFS, EAC, OS, SCCs
91  2021 Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial. HR
92  2021 Esophagectomy or Total Gastrectomy for Siewert 2 Gastroesophageal Junction (GEJ) Adenocarcinoma: An Ongoing Debate. ---
93  2021 Esophagectomy or Total Gastrectomy for Siewert 2 Gastroesophageal Junction (GEJ) Adenocarcinoma? A Registry-Based Analysis. CI, HR, NCDB, PSM
94  2021 Evolving treatment paradigms in esophageal cancer. SCC
95  2021 Genomic Heterogeneity and Clonal Evolution in Gastroesophageal Junction Cancer Revealed by Single Cell DNA Sequencing. CNVs, MALBAC, SNVs
96  2021 HER2-Directed Therapy in Advanced Gastric and Gastroesophageal Adenocarcinoma: Triumphs and Troubles. HER2
97  2021 Identification of Barrett's esophagus in endoscopic images using deep learning. BE, FCN, IoU, SCJ
98  2021 Immunotherapy in esophagogastric cancer. MSI
99  2021 Induction Chemotherapy Plus Neoadjuvant Chemoradiation for Esophageal and Gastroesophageal Junction Adenocarcinoma. IC, NCDB, nCRT, OS, pCR
100  2021 Influence of neoadjuvant therapy on outcomes in patients with resectable carcinoma of esophagus and gastro-esophageal junction from a tertiary cancer care center in India. EC, nCRT, NCT